While Pfizer has ended one of its two Phase III studies for inclacumab in sickle cell disease, the company is still eyeing an approval for the antibody in the inherited blood disorder by 2026.
Tag Archive for: antibody
While the company did not provide specific reasons for the halt, Gilead Sciences said it is “reviewing the benefit-risk” of its anti-CD47 antibody magrolimab across all ongoing trials.
Animal and early-stage human trial data for Amgen’s experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the company said on Monday.
The two companies are preparing to launch the drug in the second quarter of Eisai’s 2024/25 business year starting in April.
Japan’s Astellas Pharma said the agency declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer.
Intravenous treatment of the drug, co-developed with U.S. partner Biogen (BIIB.O), will cost about 2.98 million yen ($20,438) per patient per year.
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence biologics firm Absci to design an antibody to fight cancer.
J&J’s therapy combination of antibody treatment Rybrevant and experimental drug lazertinib showed a clinically meaningful improvement in progression-free survival rate in patients.
J&J’s therapy was tested in patients in whom the disease progressed even after they were treated with AstraZeneca’s Tagrisso.
“Efficacy and safety have not been established. There is no guarantee that NIS793 will become commercially available,” Xoma wrote in its SEC filing.
